SCHEMBL357658

SCHEMBL357658

Cn1cc(-c2ccccn2)cn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 5/20 0.60
PIM3 Q86V86 1/20 0.60
PIM2 Q9P1W9 1/20 0.60
ACVR1B P36896 1/20 0.59
TGFBR1 P36897 1/20 0.59
MAPT P10636 1/20 0.50
CHEK1 O14757 1/20 0.50
KDR P35968 2/20 0.49
CYP2A6 P11509 1/20 0.47
GRM5 P41594 1/20 0.47
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CCR1 P32246 1/20 0.46
CCR5 P51681 1/20 0.46
CCR8 P51685 1/20 0.46
METAP1 P53582 1/20 0.46
BLM P54132 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29561753 1.00 PIM1 (0.60) PIM1PIM3PIM2ACVR1BTGFBR1
SCHEMBL34466736 0.84 PIM1 (0.47) PIM1PIM3PIM2ACVR1BTGFBR1
SCHEMBL30212186 0.82 CHEK1 (0.48) PIM1PIM3PIM2ACVR1BTGFBR1
SCHEMBL34466141 0.82 PIM1 (0.48) PIM1PIM3PIM2ACVR1BTGFBR1
SCHEMBL21899128 0.79 PIM1 (0.44) PIM1PIM3PIM2ACVR1BTGFBR1
SCHEMBL18086773 0.77 KDR (0.46) PIM1PIM3PIM2ACVR1BTGFBR1
SCHEMBL20324964 0.77 KDR (0.46) PIM1PIM3PIM2ACVR1BTGFBR1
SCHEMBL11983571 0.76 CCR1 (0.55) PIM1PIM3PIM2ACVR1BTGFBR1
SCHEMBL12535908 0.76 FYN (0.50) PIM1MAPTCHEK1KDRMAPK1
SCHEMBL12503535 0.76 MAPT (0.46) PIM1PIM3PIM2ACVR1BTGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2025-03-13 US disclosed
WO-2024014851-A1 NOVEL PURINE DERIVATIVE COMPOUNDS AS HIF-1 PROTEIN INHIBITOR 주식회사 넥스트젠바이오사이언스 2024-01-18 WO disclosed
EP-4214198-A1 HETEROAROMATIC COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-07-26 EP disclosed
US-20230203030-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS ARVINAS OPERATIONS, INC. 2023-06-29 US disclosed
US-20230203030-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS ARVINAS OPERATIONS, INC. 2023-06-29 US disclosed
WO-2023104111-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) 2023-06-15 WO disclosed
EP-4126844-A1 AMIDE COMPOUNDS AND USES THEREOF Hutchison Medipharma Limited (CN) 2023-02-08 EP disclosed
US-20220402875-A1 S1P3 Antagonists TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2022-12-22 US disclosed
CN-110452216-B Anti-fibrotic pyridinones 英特穆恩公司 2022-08-26 CN disclosed
CN-114450005-A Compounds for the treatment of neurological disorders 星座制药公司 2022-05-06 CN disclosed
US-20100197914-A1 Purine Derivatives as Adenosine Al Receptor Ligands NOVARTIS AG (CH) 2010-08-05 US disclosed
US-20100197914-A1 Purine Derivatives as Adenosine Al Receptor Ligands NOVARTIS AG (CH) 2010-08-05 US disclosed
WO-2010010288-A2 ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-01-28 WO disclosed
WO-2009050199-A1 PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS NOVARTIS AG (CH) 2009-04-23 WO disclosed
WO-2008140895-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-11-20 WO disclosed
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 US disclosed
US-4881965-A CONTROLLING WILD OATS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1989-11-21 US disclosed
EP-0318602-A1 Pyrazolesulfonamide derivative, process for its production and herbicide containing it NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1989-06-07 EP disclosed
CN-86100911-A The preparation method of pyrazoles sulfone amide derivative and the weedicide that contains this kind derivative 1986-09-24 CN disclosed
EP-0189069-A2 Pyrazolesulfonamide derivative, process for its production and herbicide containing it NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1986-07-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250084074-A1 SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS VHL, CDKN1A, CCNI PIM1 1670/4885PIM3 2723/4885PIM2 2412/4885
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES BRAF, RET, KIT PIM1 81/4885PIM3 100/4885PIM2 107/4885
US-20220402875-A1 S1P3 Antagonists S1PR3, S1PR5, S1PR1 PIM1 3423/4885PIM3 1795/4885PIM2 3316/4885
US-20100197914-A1 Purine Derivatives as Adenosine Al Receptor Ligands ADORA2A, ADORA1, ADORA3 PIM1 4519/4885PIM3 4693/4885PIM2 4653/4885
US-20230203030-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS VHL, MDM2, XIAP PIM1 963/4885PIM3 1172/4885PIM2 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.